EL7.AI
StocksMediumUpdated•Originally published 30 March 2026•Updated 1 April 2026•
1 min read

Medicus Pharma Reports 80% Response Rate in SkinJect Phase 2 Clinical Trials

Key Facts

1Medicus Pharma reported an 80% overall response rate (ORR) in Phase 2 data for SkinJect.
2Dr. Babar Rao (KOL) validated that the outcomes are clinically meaningful for treating non-melanoma skin cancer.
3The treatment could potentially allow the majority of lesions to avoid immediate surgery.

Medicus Pharma (MDCX) has announced the successful validation of its Phase 2 clinical trial data for SkinJect, reporting a significant overall response rate (ORR) of 80%. Following the initial report, the company issued formal guidance to clarify the interpretation of the Phase 2 topline dataset. This clarification emphasizes a specific focus on drug-driven efficacy in the treatment of non-melanoma skin cancer. Dr. Babar Rao, acting as a Key Opinion Leader (KOL), confirmed that these outcomes are clinically meaningful and support the drug's viability as a non-surgical alternative. The treatment could potentially allow a majority of patients to avoid immediate surgical intervention and its associated risks. Analysts view this detailed guidance as a move to strengthen investor confidence in the company's lead product and its future prospects in the biotech market.